SB 418 would require health care service plans and health insurers that offer outpatient prescription drug benefits to cover up to a 12‑month supply of FDA‑approved prescription hormone therapy, plus the supplies needed for self‑administration, when prescribed by an in‑network provider and dispensed at one time. The bill also requires a pharmacist, at a patient’s request, to dispense up to a 12‑month supply except in limited circumstances (controlled substances, provider instruction, acute shortages, or patient request for a smaller quantity).
Separately, the bill imposes broad nondiscrimination duties on plans and insurers, defining discrimination on the basis of sex to include sex characteristics, pregnancy, sexual orientation, and gender identity, and prohibiting coverage denials, categorical exclusions, and discriminatory benefit designs.
Why it matters: the measure removes a common utilization control lever for continuous hormone therapy and extends a 12‑month dispensing model already applied to contraceptives to a wider class of prescription hormones. That change affects plan benefit design, pharmacy logistics, Medi‑Cal administration, and clinical monitoring practices.
The nondiscrimination provisions create affirmative notice and grievance requirements for plans and insurers and place new compliance obligations on delegated entities.
At a Glance
What It Does
The bill requires covered plans and insurers to make up to a 12‑month supply of FDA‑approved prescription hormone therapy available in a single dispensed fill and bars utilization controls that limit the supply to less than 12 months. It requires pharmacists to honor a patient’s request for a 12‑month supply unless a statutory exception applies, and it adds nondiscrimination rules prohibiting denials or categorical exclusions tied to sex or gender identity.
Who It Affects
The mandate directly affects licensed health care service plans and health insurers that provide outpatient drug benefits in California, community and retail pharmacies, prescribing clinicians, and Medi‑Cal (with specific implementation conditions). It also touches delegated entities (medical groups, IPAs) since plans must ensure delegated compliance.
Why It Matters
By legally restricting utilization management for hormone therapy, the bill shifts financial and operational risk from patients and prescribers onto payers and dispensing infrastructure. Compliance will require benefit‑design changes, updates to pharmacy dispensing protocols, and, for Medi‑Cal, coordination with federal requirements — all of which have cost, supply‑chain, and clinical‑safety implications for payers, pharmacies, and the state.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SB 418 creates two linked policy strands: access to longer‑term supplies of prescription hormone therapy, and expanded nondiscrimination protections in health coverage. On the access side, the bill defines “prescription hormone therapy” broadly to include FDA‑approved drugs used to suppress, increase, or replace hormones and requires plans and insurers that cover outpatient drugs to allow up to a 12‑month supply to be dispensed at once when prescribed by a network provider.
The law prohibits plans and insurers from applying utilization controls that would limit an authorized dispensing to less than 12 months, but it permits limits on refills during the final quarter of a plan or policy year if a year’s supply has already been dispensed. The rule applies only to products that can be stored safely at room temperature and excludes GLP‑1 products; controlled substances remain subject to state and federal dispensing limits.
The pharmacy rule in the Business and Professions Code mirrors the payer mandate from the dispensing end: a pharmacist must dispense a 12‑month supply at the patient’s request unless the patient or prescribing clinician requests a smaller amount, a temporary 90‑day cap is required by an acute shortage, the medicine is a controlled substance, or dispensing would violate an enumerated statutory prohibition. The provision does not force prescribers to write for 12 months and leaves standard pharmacy safety obligations intact.On nondiscrimination, SB 418 adds provisions to both the Health and Safety Code (for plans) and the Insurance Code (for insurers) that bar exclusion from enrollment or denial of benefits on the basis of race, color, national origin, age, disability, or sex — where “sex” expressly includes sex characteristics, pregnancy, sexual orientation, and gender identity.
The text prohibits categorical exclusions for gender‑affirming care, discriminatory marketing or benefit design, and coverage denials that function as pretexts for bias. Plans and insurers must include notices in evidences of coverage and publish grievance processes for discrimination complaints.Medi‑Cal receives separate treatment: the bill extends a 12‑month dispensing option to Medi‑Cal beneficiaries for room‑temperature‑stable hormone therapies but makes implementation contingent on any required federal approvals and available federal financial participation.
The statute explicitly excludes Medi‑Cal managed care plans that contract with the State Department of Health Care Services from the plan‑level requirements. Lastly, most of the coverage and dispensing provisions sunset on January 1, 2035, creating a ten‑year window for implementation and evaluation.
The Five Things You Need to Know
The law defines “prescription hormone therapy” to include all FDA‑approved hormone drugs as of Jan 1, 2025, and future FDA approvals used to alter hormone levels, but it explicitly excludes glucagon‑like peptide‑1 (GLP‑1) drugs and GLP‑1 receptor agonists.
If a plan’s network lacks access to medically necessary FDA‑approved hormone therapy, the plan must arrange for the drug to be provided by an out‑of‑network provider rather than leave the enrollee without coverage.
Plans and insurers and any delegated entities (medical groups, IPAs) must comply with the 12‑month dispensing rule — delegations do not relieve the plan/insurer of responsibility for compliance.
Medi‑Cal coverage for a 12‑month supply is limited to room‑temperature‑stable therapies, is subject to federal approval and funding, and the statute excludes Medi‑Cal managed care plans contracting with DHCS from the plan‑level mandate.
All of the new coverage and dispensing requirements include a sunset: the sections remain in effect only until January 1, 2035, after which they are repealed.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Legislative intent
This short preamble states the Legislature’s goal: expand existing state policy to require year‑long supplies of prescription hormone therapy across plans, insurers, and Medi‑Cal. Intent clauses do not create obligations but frame legislative purpose for regulators and courts when interpreting ambiguous provisions.
Pharmacist dispensing rule and exceptions
This section obligates pharmacists to dispense up to a 12‑month supply of FDA‑approved prescription hormone therapy at a patient’s request, unless the patient or prescriber requests a smaller amount, an acute shortage temporarily limits dispensed quantities to 90 days, the drug is a controlled substance (in which case federal/state maximums apply), or dispensing would violate specific statutory prohibitions. Practically, pharmacies must adjust inventory, ordering, and point‑of‑sale systems to support larger single fills and implement exception workflows for shortages and controlled substances.
Nondiscrimination duties for health care service plans
The bill adds a statutory nondiscrimination standard for licensed health care service plans: enrollees cannot be excluded from enrollment or denied benefits based on protected characteristics, and sex discrimination expressly covers gender identity, intersex traits, sexual orientation, pregnancy, and sex stereotypes. The section prohibits categorical exclusions for gender‑affirming care, discriminatory benefit design or marketing, and requires plan notices and grievance information in enrollee materials. Enforcement language preserves other state remedies and regulatory authority, leaving multiple enforcement avenues open to aggrieved enrollees and the department.
Plan coverage mechanics and limits
This operative provision imposes the 12‑month coverage requirement on health care service plan contracts that include outpatient drug benefits: plans must cover a full year’s supply prescribed by a network provider and dispensed at one time, may limit refills in the final quarter if a year’s supply was already dispensed, and may not impose utilization controls that cap dispensed supply below 12 months. The rule applies only to room‑temperature‑stable therapies and exempts experimental treatments. If the plan delegates administration, the delegated entity must follow the law; however, out‑of‑network coverage is only required where network access is unavailable under applicable law or the plan’s policies.
Parallel coverage and nondiscrimination rules for insurers
These mirrored Insurance Code sections extend the 12‑month dispensing and nondiscrimination obligations to regulated health insurers. The operative mechanics and definitions largely replicate the plan provisions: insurers cannot use utilization controls to limit dispensed supplies below 12 months, must support network or arranged out‑of‑network access, and must include discrimination notices and grievance routes in policy documents. Delegated entities must comply when insurers assign responsibilities to third parties.
Medi‑Cal coverage and federal coordination
This section directs Medi‑Cal to cover up to a 12‑month supply of room‑temperature‑stable FDA‑approved prescription hormone therapy and necessary self‑administration supplies, subject to utilization controls and medical necessity. Implementation requires the department to seek necessary federal approvals and available federal financial participation; the section explicitly excludes Medi‑Cal managed care plans contracting with DHCS from the plan‑level statutory mandate, signaling a different pathway (or potential gap) for beneficiaries enrolled in managed care.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Transgender, nonbinary, and intersex patients on maintenance hormone therapy — they gain fewer pharmacy visits, more consistent supply, and lower risk of lapses that can destabilize treatment plans or force emergency care.
- Rural and mobility‑limited patients — a 12‑month dispensing option reduces travel burdens and the need for frequent refills where pharmacies are distant or transportation is limited.
- Clinicians prescribing long‑term hormone therapy — fewer administrative barriers (fewer refill/authorization requests) and more predictable continuity of care when patients can obtain year‑long supplies.
- Community health centers and safety‑net clinics — reduced visit cadence for medication refills can free clinical time and reduce no‑show rates tied to prescription access.
Who Bears the Cost
- Health insurers and health care service plans — they must change benefit design, adapt utilization‑management systems, absorb higher single‑fill dispensing costs, and potentially pay higher up‑front pharmacy reimbursements or face higher inventory costs.
- Pharmacies and pharmacists — larger single fills increase upfront purchasing and cash‑flow pressure, require changes to inventory management and POS systems, and carry responsibility for triaging exceptions and shortages.
- Department of Health Care Services/Medi‑Cal administration — DHCS must seek federal approvals, identify funding strategies for expanded coverage, and manage the exclusion of managed care plans, which could create administrative complexity and uneven beneficiary experiences.
- Delegated entities (medical groups, IPAs) — where plans contract out administration, those entities must update their policies and pharmacy networks to comply, which imposes contractual, operational, and IT costs.
Key Issues
The Core Tension
The bill resolves one problem — gaps and friction in access to continuous hormone therapy — by constraining payers and dispensers, but in doing so it forces a trade‑off between easier patient access and payers’ and pharmacists’ ability to manage clinical safety, cost, and supply logistics; reasonable stakeholders will disagree about where to draw that line.
SB 418 prioritizes patient access, but it creates several implementation and policy tensions. First, removing utilization controls for a 12‑month dispensed fill shifts clinical‑risk management and cost exposure upstream to payers and dispensing points; insurers will need to revise formularies, prior‑authorization logic, and reimbursement models to account for larger single fills while still ensuring safety monitoring and adherence.
Pharmacies will absorb upfront purchasing and inventory risks, particularly smaller independent pharmacies that lack capital to purchase larger quantities for single fills.
Second, the bill draws a line around which therapies qualify: only FDA‑approved, room‑temperature‑stable hormone drugs are covered (explicitly excluding GLP‑1s). That technical limit will produce uneven coverage across products and may require future clarifying guidance about borderline cases (cold‑chain products; compounded preparations).
The exclusion of Medi‑Cal managed care plans from the plan‑level mandate creates a practical disparity: fee‑for‑service Medi‑Cal beneficiaries may see different access rules than beneficiaries in managed care, and DHCS must pursue federal waivers or state plan amendments before the benefit can be broadly operationalized.
Finally, the nondiscrimination provisions introduce broad, enforceable duties with overlapping remedies (state anti‑discrimination statutes, plan grievance procedures, civil penalties), but the text leaves open how regulators will balance legitimate clinical‑medical‑necessity determinations against claims of pretextual discrimination. That tension will require carefully drafted regulatory guidance and interagency coordination to avoid chilling appropriate medical management while preventing discriminatory denials.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.